Abstract: The present invention relates to methods of treating disease states, including cancer, in a human comprising systemically administering a STING agonist, or a pharmaceutically acceptable salt thereof, to said human.

Abstract: The present invention relates to a method of manufacturing and using heat shock proteins containing a step of initiating a coagulative necrotic process in a tissue. In particular, a method of manufacturing and using heat shock proteins comprises the steps of heating a tissue to initiate the coagulative necrotic process for a period of time, cooling the tissue, incubating the tissue in an appropriate growth medium, and collecting the supernatant from the tissue. In a preferred embodiment, the coagulative necrotic process is initiated by heating the tissue to 60°; or more. The tissue is then cooled to room temperature before incubating the tissue in growth media for 48 hours or less. Heat shock proteins produced in accordance with this method may be complexed to peptides or antigens to produce autologous vaccines in the prevention and treatment of various diseases. Furthermore, heat shock proteins may be used in diagnostic assays for various autoimmune and inflammatory diseases.